Harmonizing EU Health Legislation for New Genomic Techniques

This article examines the regulation and application of New Genomic Techniques (NGTs) and genetic testing within the European Union (EU). It scrutinises the detailed aspects of EU data protection laws, underscoring their significance in safeguarding patient privacy and facilitating data sharing in healthcare and research sectors. The paper delves into the ethical dimensions and technological advances in genetic engineering, specifically focusing on gene editing and direct-to-consumer genetic testing, illuminating the complex interplay between technology, ethics, and legal frameworks. The analysis extends to the diverse regulatory environments at both national and EU levels, highlighting the urgent need for legislative updates in response to the rapid advancements in genomic technologies. This necessity accentuates the ongoing challenge of balancing fostering innovation and adhering to ethical and legal standards. Moreover, the article addresses the efforts to harmonise genetic testing regulations across European nations, considering the perspectives of multiple stakeholders. The discourse presented in the article underscores the complexity and critical importance of formulating policies that safeguard public interests and propel scientific advancements in this swiftly evolving domain. The EU should enhance the regulation and standardisation of NGTs in the field of human health and medicine by updating legislation, implementing risk assessment and safety protocols, establishing ethical guidelines, involving various stakeholders, adhering to global standards, promoting public education, and integrating NGTs into healthcare systems, ultimately aiming to promote safe and ethical NGTs development and advance public health objectives.